JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

Autor: Jiri Mayer, Hans Carl Hasselbalch, Zdenek Racil, Lijuan Han, Angela Maurer, Anders Lindholm Sørensen, Deniz Gezer, Claudia Schubert, Julia Czech, Ivan G. Costa, Sabrina Cordua, Tim H. Brümmendorf, Barbora Weinbergerova, Nicolas Chatain, Morten Orebo Holmström, Lasse Kjær, Trine Alma Knudsen, Bernd Denecke, Thomas Stauffer Larsen, Vibe Skov, Julian Baumeister, Steffen Koschmieder, Kristina Feldberg, Blanka Kubešová, Tiago Maié, Gerhard Müller-Newen, Assja Crepcia

Publikováno v: Czech, J, Cordua, S, Weinbergerova, B, Baumeister, J, Crepcia, A, Han, L, Maié, T, Costa, I G, Denecke, B, Maurer, A, Schubert, C, Feldberg, K, Gezer, D, Brümmendorf, T H, Müller-Newen, G, Mayer, J, Racil, Z, Kubesova, B, Knudsen, T, Sørensen, A L, Holmström, M, Kjær, L, Skov, V, Larsen, T S, Hasselbalch, H C, Chatain, N & Koschmieder, S 2019, ' JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation ', Leukemia, vol. 33, no. 4, pp. 995-1010 . https://doi.org/10.1038/s41375-018-0295-6

Pegylated interferon-α (peg-IFNa) treatment induces molecular responses (MR) in patients with myeloproliferative neoplasms (MPNs), including partial MR (PMR) in 30–40% of patients. Here, we compared the efficacy of IFNa treatment in JAK2V617F- vs.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56f5523d5077aee3a85880cb282335b6
https://doi.org/10.1038/s41375-018-0295-6